Navigation Links
Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.

BETHESDA, Md., July 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported that the Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), will expand outside of the United States. Several countries with high prevalence of treatment-naive type II diabetics are being considered. "This expansion abroad should allow us to finish enrollment in the first quarter of 2009, which is consistent with the timeline reported at the recent Shareholders Meeting. What makes the sites we are considering so attractive is their ability to gain regulatory approval and recruit a large number of patients in a very short period of time," said Randy W. Brown, Chief of Operations. Mr. Brown reported that, as of June 30, 2008, 155 subjects of the required 450 have been randomized into the trial and are under study.

Recent media reports in the U.S. about the Phase 3 trial have accelerated inquiries by prospective patients who would like to participate in the trial. Stories appeared in Maryland's Baltimore Sun and on Pittsburgh, Pennsylvania's KDKA following publication of a report in the peer-reviewed journal Diabetes, Obesity And Metabolism(1-3). Thomas Donner, M.D., medical director of University of Maryland's Joslin Diabetes Center, said that if the drug works on diabetes, there could be more trials to show efficacy in weight reduction. Dr. Donner has noted that people in previous smaller trials also lost weight.

The Company also announced that it has successfully petitioned the FDA to eliminate the need for pre-mixed solutions for the delivery of study medicine to participants. "This convenient form of dosing reflects the expected delivery method of Naturlose once it gains approval. The change is expected to enhance recruitment and compliance in the trial. This is a significant advancement for the Company, our investigators and their patients," said Mr. Brown.

1. Yongming Lu, Gilbert Levin, Thomas Donner. "Tagatose, a New Anti-Diabetic and Obesity-Control Drug." Diabetes, Obesity and Metabolism. 10, 2008, 109-134.

2. Meredith Cohn, "Sweet Hope, The natural sugar tagatose, once a Slurpee sweetener, could help diabetes patients control blood glucose levels." Baltimore Sun, March 27, 2008.

3. Sugar Treatment Could Help Diabetes Patients, Jun 30, 2008 8:21 pm US/Eastern, (click on "Related" to watch the video).

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix D-tagatose to be Supplied by Inalco SpA
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix Reports Second Quarter Earnings
4. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
5. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
6. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
7. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
8. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
9. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
Post Your Comments:
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):